Drug Trial Radar · NCT06858332
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,382
Planned (sponsor's estimate)
Start
Apr 15, 2025
Primary completion
Sep 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 5, 2025
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (CVD) risk.
Conditions
- Atherosclerotic Cardiovascular Disease
Interventions
AtorvastatinDrug
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
SimvastatinDrug
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
RozuvastatinDrug
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
EzetimibeDrug
Ezetimibe
NiacinDrug
Niacin
CiprofibrateDrug
Fibrates
FenofibrateDrug
Fibrates
BezafibrateDrug
Fibrates
EvolocumabDrug
PCSK9 inhibitor
AlirocumabDrug
PCSK9 inhibitor
InclisiranDrug
Small interfering RNA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients (%) with Lp(a) ≥125 nmol/LTime frame: Baseline
- The difference in the number of patients with cardiovascular events (%) between the groupsTime frame: 24 months
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Chelyabinsk, Russia · Recruiting
Novartis Investigative Site
Chelyabinsk, Russia · Recruiting
Novartis Investigative Site
Kaluga, Russia · Recruiting
Novartis Investigative Site
Kemerovo, Russia · Recruiting
Novartis Investigative Site
Krasnoyarsk, Russia · Recruiting
Novartis Investigative Site
Moscow, Russia · Recruiting
Novartis Investigative Site
Moscow, Russia · Recruiting
Novartis Investigative Site
Moscow, Russia · Recruiting
Novartis Investigative Site
Omsk, Russia · Recruiting
Novartis Investigative Site
Perm, Russia · Recruiting
Novartis Investigative Site
Ryazan, Russia · Recruiting
Novartis Investigative Site
Surgut, Russia · Recruiting
Novartis Investigative Site
Tomsk, Russia · Recruiting
Novartis Investigative Site
Tyumen, Russia · Recruiting
Novartis Investigative Site
Vladimir, Russia · Recruiting
Novartis Investigative Site
Vladivostok, Russia · Recruiting
Novartis Investigative Site
Voronezh, Russia · Recruiting
Novartis Investigative Site
Yakutsk, Russia · Recruiting
Novartis Investigative Site
Yekaterinburg, Russia · Recruiting
Novartis Investigative Site
Yekaterinburg, Russia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.